Results from the BLAZE-1 study of combined bamlanivimab/etesevimab, showing significantly lower mortality and combined mortality/hospitalization with treatment.
Lilly et al., 3/10/2021, Double Blind Randomized Controlled Trial, preprint, 1 author.
risk of death, 92.3% lower, RR 0.08, p = 0.01, treatment 0 of 511 (0.0%), control 4 of 258 (1.6%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of combined hospitalization/death, 86.5% lower, RR 0.13, p < 0.001, treatment 4 of 511 (0.8%), control 15 of 258 (5.8%).
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.